(Q28275476)

English

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

scientific article

In more languages

Statements

scholarly article

0 references

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (English)

0 references

0 references

abiraterone acetate

1 reference

ChEBI release 2020-05-28

prostate cancer

1 reference

based on heuristic

inferred from title

1

object named as

Karim Fizazi

0 references

10

object named as

Fred Saad

0 references

2

object named as

Howard I Scher

0 references

14

object named as

Cora N Sternberg

0 references

Nicholas J. Vogelzang

9

object named as

Nicholas J Vogelzang

0 references

author name string

Arturo Molina

3

0 references

Christopher J Logothetis

4

0 references

Kim N Chi

5

0 references

Robert J Jones

6

0 references

John N Staffurth

7

0 references

Scott North

8

0 references

Paul Mainwaring

11

0 references

Stephen Harland

12

0 references

Oscar B Goodman

13

0 references

Jin Hui Li

15

0 references

Thian Kheoh

16

0 references

Christopher M Haqq

17

0 references

Johann S de Bono

18

0 references

language of work or name

0 references

publication date

October 2012

0 references

Lancet Oncology Commission

0 references

13

0 references

10

0 references

983-92

0 references

Secondary hormonal therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Understanding the epidemiology, natural history, and key pathways involved in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Castration-resistant prostate cancer: locking up the molecular escape routes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The androgen axis in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting continued androgen receptor signaling in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The postchemotherapy PSA surge syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970379-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70379-0

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28275476&oldid=2201351311"